Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

The mechanisms of action of PPARs

Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659 · see citing works

Roles of PPARs in health and disease

Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · see citing works

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730 · see citing works

Adipogenesis and Obesity: Rounding Out the Big Picture

Spiegelman, B. M., & Flier, J. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81359-8 · Cited by 1,254 · see citing works

Terminal Differentiation of Human Breast Cancer through PPARγ

Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., & Spiegelman, B. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80047-7 · Cited by 850 · see citing works

Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

Elstner, E., Müller‐Tidow, C., Koshizuka, K., Williamson, E. A., Park, D. J., Asou, H., Shintaku, P. I., SAID, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 805 · see citing works

The Structure−Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the Antihyperglycemic Activity of Thiazolidinediones

Willson, T. M., Cobb, J. E., Cowan, D. J., Wiethe, R. W., Correa, I. D., Prakash, S. R., Beck, K. D., Moore, L. B., Kliewer, S. A., & Lehmann, J. M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950395a · Cited by 638 · see citing works

Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., SAID, J. W., Holden, S. A., Miyoshi, I., & Koeffler, H. P. (1998) · PubMed · Cited by 589 · see citing works

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma

Demetri, G. D., Fletcher, C. D. �., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., & Singer, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3951 · Cited by 495 · see citing works

Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer

Mueller, E., Smith, M. R., Sarraf, P., Kroll, T. G., Aiyer, A., Kaufman, D. S., Oh, W. K., Demetri, G. D., Figg, W. D., Zhou, X.-P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180329197 · Cited by 427 · see citing works

Nonhypoglycemic Effects of Thiazolidinediones

Parulkar, A., Pendergrass, M., Granda-Ayala, R., Lee, T. R., & Fonseca, V. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-1-200101020-00014 · Cited by 410 · see citing works

Lessons from the glitazones: a story of drug development

Gale, E. A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04960-6 · Cited by 289 · see citing works

APC-dependent suppression of colon carcinogenesis by PPARγ

Girnun, G. D., Smith, W. M., Drori, S., Sarraf, P., Mueller, E., Eng, C., Nambiar, P. R., Rosenberg, D. W., Bronson, R. T., Edelmann, W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162480299 · Cited by 277 · see citing works

A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.

Suh, N., Wang, Y., Williams, C. R., Risingsong, R., Gilmer, T. M., Willson, T. M., & Sporn, M. B. (1999) · PubMed · Cited by 230 · see citing works

Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.

Rubin, G., Zhao, Y., Kalus, A. M., & Simpson, E. R. (2000) · PubMed · Cited by 190 · see citing works

A Ligand of Peroxisome Proliferator-Activated Receptor gamma, Retinoids, and Prevention of Preneoplastic Mammary Lesions

Mehta, R. G. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.418 · Cited by 147 · see citing works

Troglitazone Inhibits Growth of MCF-7 Breast Carcinoma Cells by Targeting G1 Cell Cycle Regulators

Yin, F., Wakino, S., Liu, Z., Kim, S., Hsueh, W. A., Collins, A. R., Herle, A. J. V., & Law, R. E. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5491 · Cited by 143 · see citing works

Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer

Esteva, F. J., Glaspy, J. A., Baidas, S. M., Laufman, L. R., Hutchins, L. F., Dickler, M. N., Tripathy, D., Cohen, R., DeMichele, A. M., Yocum, R. C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.068 · Cited by 115 · see citing works

Troglitazone

Spencer, C. M., & Markham, A. (1997) · Drugs · doi:10.2165/00003495-199754010-00010 · Cited by 93 · see citing works

The peroxisome proliferator-activated receptor γ is an inhibitor of ErbBs activity in human breast cancer cells

Pignatelli, M., Cortés‐Canteli, M., Lai, C., Santos, Á., & Pérez‐Castillo, A. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.22.4117 · Cited by 58 · see citing works

PPARγ and colorectal carcinoma: Conflicts in a nuclear family

Seed, B. (1998) · Nature Medicine · doi:10.1038/1990 · Cited by 45 · see citing works

Diabetes and Cancer

Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · see citing works

Fat and Beyond: The Diverse Biology of PPARγ

Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085 · see citing works

Diabetes and Cancer: A Consensus Report

Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,065 · see citing works

Obesity and diabetes: the increased risk of cancer and cancer-related mortality

Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806 · see citing works

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention

Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3214 · Cited by 494 · see citing works

Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists

Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 440 · see citing works

Diabetes mellitus and breast cancer

Wolf, I., Sadetzki, S., Catane, R., Karasik, A., & Kaufman, B. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)01736-5 · Cited by 422 · see citing works

Crosstalk Between Peroxisome Proliferator-Activated Receptor Gamma and the Canonical WNT/β-Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis

Vallée, A., & Lecarpentier, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00745 · Cited by 352 · see citing works

Differentiation therapy of leukemia: 3 decades of development.

Nowak, D., Stewart, D., & Koeffler, H. P. (2009) · Blood · doi:10.1182/blood-2009-01-198911 · Cited by 348 · see citing works

Paracrine and Endocrine Effects of Adipose Tissue on Cancer Development and Progression

Park, J., Euhus, D., & Scherer, P. E. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0030 · Cited by 349 · see citing works

15d-PGJ2: The anti-inflammatory prostaglandin?

Scher, J. U., & Pillinger, M. H. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.09.008 · Cited by 348 · see citing works

Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

Cheng, H. S., Tan, W., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 272 · see citing works

PPAR-α Modulators as Current and Potential Cancer Treatments

Chi, T., Wang, M., Wang, X., Ke, Y., Xie, F., Zehuan, L., & Wei, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.599995 · Cited by 244 · see citing works

Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy

Shlomai, G., Neel, B. A., LeRoith, D., & Gallagher, E. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4044 · Cited by 237 · see citing works

Peroxisome proliferator–activated receptor-δ attenuates colon carcinogenesis

Harman, F. S., Nicol, C. J. B., Marin, H. E., Ward, J. M., Gonzalez, F. J., & Peters, J. M. (2004) · Nature Medicine · doi:10.1038/nm1026 · Cited by 214 · see citing works

GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation

Seargent, J. M., Yates, E., & Gill, J. H. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705973 · Cited by 193 · see citing works

Mechanisms of Disease: adipokines and breast cancer—endocrine and paracrine mechanisms that connect adiposity and breast cancer

Schäffler, A., Schölmerich, J., & Buechler, C. (2007) · Nature Clinical Practice Endocrinology &#38 Metabolism · doi:10.1038/ncpendmet0456 · Cited by 185 · see citing works

Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment

Suh, S., & Kim, K. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0177 · Cited by 185 · see citing works

PPARγ signaling exacerbates mammary gland tumor developmentPreprint

Sáez, E., Rosenfeld, J. M., Livolsi, A., Olson, P., Lombardo, E., Nelson, M. C., Banayo, E., Cardiff, R. D., Izpisúa‐Belmonte, J. C., & Evans, R. M. (2004) · Genes & Development · doi:10.1101/gad.1167804 · Cited by 178 · see citing works

Peroxisome proliferator-activated receptors and cancer: challenges and opportunities

Youssef, J., & Badr, M. Z. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01383.x · Cited by 156 · see citing works

PPARβ/δ selectively induces differentiation and inhibits cell proliferation

Kim, D. J., Bility, M. T., Billin, A. N., Willson, T. M., Gonzalez, F. J., & Peters, J. M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401713 · Cited by 146 · see citing works

Thiazolidinediones as anti-cancer agents.

Blanquicett, C., Roman, J., & Hart, C. M. (2008) · PubMed · Cited by 141 · see citing works

Minireview: Nuclear Receptors and Breast Cancer

Conzen, S. D. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0421 · Cited by 141 · see citing works

Peroxisome Proliferator-Activated Receptor-γ Activation Inhibits Tumor Metastasis by Antagonizing Smad3-Mediated Epithelial-Mesenchymal Transition

Reka, A. K., Kurapati, H., Narala, V. R., Bommer, G. T., Chen, J., Standiford, T. J., & Keshamouni, V. G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0570 · Cited by 136 · see citing works

Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARγ) in K562 cancer cells

Zhang, X., Zhao, W., Hu, L., Zhao, L., & Huang, J. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.05.004 · Cited by 135 · see citing works

Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics?

Han, S., & Roman, J. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328011e67d · Cited by 135 · see citing works

Peroxisome proliferator-activated receptor γ in malignant diseases

WANG, T., Xu, J., Yu, X., Yang, R., & Han, Z. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.08.011 · Cited by 127 · see citing works

Adipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer Risk

Tumminia, A., Vinciguerra, F., Parisi, M., Graziano, M., Sciacca, L., Baratta, R., & Frittitta, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122863 · Cited by 128 · see citing works

Synergy between PPARγ Ligands and Platinum-Based Drugs in Cancer

Girnun, G. D., Naseri, E., Vafai, S. B., Qu, L., Szwaya, J. D., Bronson, R. T., Alberta, J. A., & Spiegelman, B. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.025 · Cited by 128 · see citing works

Peroxisome Proliferator-Activated Receptor γ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention

Ondrey, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0326 · Cited by 126 · see citing works

Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC)

Bren‐Mattison, Y., Putten, V. V., Chan, D. C. F., Winn, R. A., Geraci, M. W., & Nemenoff, R. A. (2004) · Oncogene · doi:10.1038/sj.onc.1208333 · Cited by 117 · see citing works

PPAR‐γAgonists and Their Effects on IGF‐I Receptor Signaling: Implications for Cancer

Belfiore, A., Genua, M., & Malaguarnera, R. (2009) · PPAR Research · doi:10.1155/2009/830501 · Cited by 116 · see citing works

Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

Davidson, M., Mattison, D. R., Azoulay, L., & Krewski, D. R. (2017) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 114 · see citing works

Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours

Park, J., Morley, T. S., & Scherer, P. E. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202006 · Cited by 111 · see citing works

Research Resource: Nuclear Receptors as Transcriptome: Discriminant and Prognostic Value in Breast Cancer

Muscat, G. E. O., Eriksson, N. A., Byth, K., Loi, S., Graham, J. D., Jindal, S., Davis, M. J., Clyne, C. D., Funder, J. W., Simpson, E. R., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1265 · Cited by 111 · see citing works

Chemotherapy and Chemoprevention by Thiazolidinediones

Fröhlich, E., & Wahl, R. (2015) · BioMed Research International · doi:10.1155/2015/845340 · Cited by 105 · see citing works

Peroxisomal Proliferator-Activated Receptor-γ Agonists Induce Partial Reversion of Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer Cells

Aiello, A., Pandini, G., Frasca, F., Conte, E., Murabito, A., Sacco, A., Genua, M., Vigneri, R., & Belfiore, A. (2006) · Endocrinology · doi:10.1210/en.2005-1610 · Cited by 105 · see citing works

Hic-5 regulates an epithelial program mediated by PPARγPreprint

Drori, S., Girnun, G. D., Tou, L., Szwaya, J. D., Mueller, E., Kia, X., Shivdasani, R. A., & Spiegelman, B. M. (2005) · Genes & Development · doi:10.1101/gad.1240705 · Cited by 102 · see citing works

A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands

Crowe, D. L., & Chandraratna, R. A. S. (2004) · Breast Cancer Research · doi:10.1186/bcr913 · Cited by 101 · see citing works

Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers

Yee, L. D., Williams, N., Wen, P., Young, D. C., Lester, J., Johnson, M. V., Farrar, W. B., Walker, M. J., Povoski, S. P., Suster, S. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1947 · Cited by 98 · see citing works

The Insulin Receptor: A New Target for Cancer Therapy

Malaguarnera, R., & Belfiore, A. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00093 · Cited by 98 · see citing works

PPAR gamma, bioactive lipids, and cancer progression

Gregory, T. (2011) · Frontiers in bioscience · doi:10.2741/4021 · Cited by 95 · see citing works

The prince and the pauper. A tale of anticancer targeted agents

Dueñas‐González, A., García‐López, P., Herrera, L. A., Medina‐Franco, J. L., González‐Fierro, A., & Candelaria, M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-82 · Cited by 91 · see citing works

Type 2 Diabetes and Cancer: What Is the Connection?

Cannata, D., Fierz, Y., Vijayakumar, A., & LeRoith, D. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20167 · Cited by 91 · see citing works

Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers

Lavudi, K., Nuguri, S. M., Olverson, Z. A., Dhanabalan, A. K., Patnaik, S., & Kokkanti, R. R. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1254612 · Cited by 89 · see citing works

Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer

Fenner, M. H., & Elstner, E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.557 · Cited by 88 · see citing works

Therapeutic potential of thiazolidinediones as anticancer agents

Panigrahy, D., Shen, L. Q., Kieran, M. W., & Kaipainen, A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.12.1925 · Cited by 88 · see citing works

Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

Girnun, G. D., Chen, L., Silvaggi, J. M., Drapkin, R., Chirieac, L. R., Padera, R. F., Upadhyay, R., Vafai, S. B., Weissleder, R., Mahmood, U., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1128 · Cited by 84 · see citing works

The chalcone butein from Rhus verniciflua Stokes inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblasts

Samoszuk, M. K., Tan, J., & Chorn, G. (2005) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-5-5 · Cited by 83 · see citing works

Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer

Caldon, C. E., Sutherland, R. L., & Musgrove, E. A. (2010) · Cell Cycle · doi:10.4161/cc.9.10.11474 · Cited by 78 · see citing works

Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture

Fröhlich, E., Machicao, F., & Whal, R. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00973 · Cited by 77 · see citing works

Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT/beta‐catenin pathway

Lecarpentier, Y., CLAES, V. A., Vallée, A., & Hébert, J. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0144-7 · Cited by 75 · see citing works

Obesity and Breast Cancer: The Roles of Peroxisome Proliferator‐Activated Receptor‐γ and Plasminogen Activator Inhibitor‐1

Carter, J. C., & Church, F. (2009) · PPAR Research · doi:10.1155/2009/345320 · Cited by 75 · see citing works

Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone

Yao, C., Lai, G., Chan, C., Cheng, A., Yang, Y., & Chuang, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21361 · Cited by 70 · see citing works

Synthesis of new troglitazone derivatives: Anti-proliferative activity in breast cancer cell lines and preliminary toxicological study

Salamone, S., Colin, C., Grillier‐Vuissoz, I., Kuntz, S., Mazerbourg, S., Flament, S., Martin, H., Richert, L., Chapleur, Y., & Boisbrun, M. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.02.044 · Cited by 67 · see citing works

The Role of PPARγ Ligands in Breast Cancer: From Basic Research to Clinical Studies

Augimeri, G., Giordano, C., Gelsomino, L., Plastina, P., Barone, I., Catalano, S., Andò, S., & Bonofiglio, D. (2020) · Cancers · doi:10.3390/cancers12092623 · Cited by 66 · see citing works

In Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone

Botton, T., Puissant, A., Bahadoran, P., Annicotte, J., Lluis Fajas, A., Ortonne, J. ‐., Gozzerino, G., Zamoum, T., Tartare‐Deckert, S., Bertolotto, C., et al. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.346 · Cited by 65 · see citing works

Cyclooxygenase-2 Expression in Human Colorectal Cancer Is Unrelated to Overall Patient Survival

Fux, R., Schwab, M. G., Thon, K., Gleiter, C. H., & Fritz, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2586 · Cited by 65 · see citing works

Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer

Berstein, L. M. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.11.011 · Cited by 63 · see citing works

Peroxisome proliferator-activated receptor γ in human breast carcinoma: a modulator of estrogenic actions

Suzuki, T., Hayashi, S., Miki, Y., Nakamura, Y., Moriya, T., Sugawara, A., Ishida, T., Ohuchi, N., & Sasano, H. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01075 · Cited by 62 · see citing works

Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone

Cheng, W. Y., Huynh, H., Chen, P., Peña‐Llopis, S., & Wan, Y. (2016) · eLife · doi:10.7554/elife.18501 · Cited by 60 · see citing works

Peroxisome Proliferator-Activated Receptor γ Is Highly Expressed in Pancreatic Cancer and Is Associated With Shorter Overall Survival Times

Kristiansen, G., Jacob, J., Buckendahl, A., Grützmann, R., Alldinger, I., Sipos, B., Klöppel, G., Bahra, M., Langrehr, J. M., Neuhaus, P., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0834 · Cited by 58 · see citing works

Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy

Khandekar, M. J., Banks, A. S., Laznik-Bogoslavski, D., White, J. P., Choi, J. H., Kazak, L., Lo, J. C., Cohen, P., Wong, K., Kamenecka, T. M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717776115 · Cited by 55 · see citing works

Specific Thiazolidinediones Inhibit Ovarian Cancer Cell Line Proliferation and Cause Cell Cycle Arrest in a PPARγ Independent Manner

Al-Alem, L., Southard, R. C., Kilgore, M. W., & Curry, T. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016179 · Cited by 53 · see citing works

Involvement of PPARγ and E‐cadherin/β‐catenin pathway in the antiproliferative effect of conjugated linoleic acid in MCF‐7 cells

Bocca, C., Bozzo, F., Francica, S., Colombatto, S., & Miglietta, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22646 · Cited by 53 · see citing works

Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urotheliumin vivo

Egerod, F. L., Nielsen, H. S., Iversen, L., Thorup, I., Storgaard, T., & Oleksiewicz, M. B. (2005) · Biomarkers · doi:10.1080/13547500500218682 · Cited by 53 · see citing works

PPARγ activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFβ signalling

Jarrar, M. H., & Baranova, A. V. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00003.x · Cited by 52 · see citing works

The Role of PPARs in Breast Cancer

Zhao, B., Xin, Z., Ren, P., & Wu, H. (2022) · Cells · doi:10.3390/cells12010130 · Cited by 50 · see citing works

Activating Peroxisome Proliferator-Activated Receptor γ Mutant Promotes Tumor Growth In vivo by Enhancing Angiogenesis

Tian, L., Zhou, J., Casimiro, M. C., Liang, B., Ojeifo, J. O., Wang, M., Hyslop, T., Wang, C., & Pestell, R. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2067 · Cited by 50 · see citing works

Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis

Bandera-Merchán, B., Tinahones, F. J., & Macías‐González, M. (2016) · PPAR Research · doi:10.1155/2016/2308249 · Cited by 50 · see citing works

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue

Heudobler, D., Rechenmacher, M., Lüke, F., Vogelhuber, M., Pukrop, T., Herr, W., Ghibelli, L., Gerner, C., & Reichle, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113540 · Cited by 50 · see citing works

The potential of antidiabetic thiazolidinediones for anticancer therapy

Galli, A., Mello, T., Ceni, E., Surrenti, E., & Surrenti, C. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.9.1039 · Cited by 50 · see citing works

E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model

Yoo, J. Y., Yang, S.-H., Lee, J. E., Cho, D. G., Kim, H. K., Kim, S. H., Kim, I. S., Hong, J. T., Sung, J. H., Son, B. C., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0890-8 · Cited by 49 · see citing works

Peroxisome Proliferator‐Activated Receptors: New Players in the Field of Reproduction

Tóth, B., Hornung, D., Scholz, C., Djalali, S., Friese, K., & Jeschke, U. (2007) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2007.00514.x · Cited by 48 · see citing works

Bioassay for the Identification of Natural Product-Based Activators of Peroxisome Proliferator-Activated Receptor-γ (PPARγ): The Marine Sponge Metabolite Psammaplin A Activates PPARγ and Induces Apoptosis in Human Breast Tumor Cells

Mora, F. D., Jones, D. K., Desai, P. V., Patny, A., Avery, M. A., Feller, D. R., Smillie, T. J., Zhou, Y., & Nagle, D. G. (2006) · Journal of Natural Products · doi:10.1021/np050397q · Cited by 48 · see citing works

Biotransformation of polyunsaturated fatty acids to bioactive hepoxilins and trioxilins by microbial enzymes

An, J.-U., Song, Y., Kim, K.-R., Ko, Y., Yoon, D., & Oh, D. (2018) · Nature Communications · doi:10.1038/s41467-017-02543-8 · Cited by 45 · see citing works

PPARγ Physiology and Pathology in Gastrointestinal Epithelial Cells

Thompson, E. A. (2007) · Molecules and Cells · doi:10.1016/s1016-8478(23)07325-9 · Cited by 45 · see citing works

Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients

Xuan, D. T. M., Wu, C.-C., Kao, T., Ta, H. D. K., Anuraga, G., Andriani, V., Athoillah, M., Chiao, C.-C., Wu, Y.-F., Lee, K., et al. (2021) · Aging · doi:10.18632/aging.203722 · Cited by 43 · see citing works

PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers

Chen, L., Yuan, Y., Kar, S., Kanchi, M. M., Arora, S., Kim, J. E., Koh, P. F., Yousef, E. M., Samy, R. P., Shanmugam, M. K., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0739 · Cited by 42 · see citing works

Peroxisome Proliferator‐Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies

Yousefi, B., Samadi, N., Baradaran, B., Shafiei‐Irannejad, V., & Zarghami, N. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12737 · Cited by 41 · see citing works

Peroxisome Proliferator-activated Receptor γ Agonists Induce Cell Cycle Arrest through Transcriptional Regulation of Krüppel-like Factor 4 (KLF4)

Li, S., Zhou, Q., He, H., Zhao, Y., & Liu, Z. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.317487 · Cited by 40 · see citing works

Peroxisome Proliferator‐activated Receptors and their Relevance to Dermatology

Friedmann, P. S., Cooper, H. L., & Healy, E. (2005) · Acta Dermato Venereologica · doi:10.1080/00015550510030104 · Cited by 40 · see citing works

Synergistic Effects of PPAR γ Ligands and Retinoids in Cancer Treatment

Shimizu, M., & Moriwaki, H. (2008) · PPAR Research · doi:10.1155/2008/181047 · Cited by 40 · see citing works

Peroxisome Proliferator-Activated Receptor γ and Growth Inhibition by Its Ligands in Uterine Endometrial Carcinoma

Ota, K., Ito, K., Suzuki, T., Saito, S., Tamura, M., Hayashi, S., Okamura, K., Sasano, H., & Yaegashi, N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1833 · Cited by 40 · see citing works

A Role for the PPARγ in Cancer Therapy

Campbell, M. J., Carlberg, C., & Koeffler, H. P. (2008) · PPAR Research · doi:10.1155/2008/314974 · Cited by 39 · see citing works

Disruption of ERα signalling pathway by PPARγ agonists: evidences of PPARγ-independent events in two hormone-dependent breast cancer cell lines

Lecomte, J., Flament, S., Salamone, S., Boisbrun, M., Mazerbourg, S., Chapleur, Y., & Grillier‐Vuissoz, I. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9886-z · Cited by 39 · see citing works

Peroxisome proliferator‐activated receptors as therapeutic target for cancer

Wang, Y., Lei, F., Lin, Y., Han, Y., Yang, L., & Tan, H. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17931 · Cited by 38 · see citing works

Arousal of cancer-associated stromal fibroblasts

Brentnall, T. A. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.21453 · Cited by 37 · see citing works

The Involvement of PPARs in the Peculiar Energetic Metabolism of Tumor Cells

Antonosante, A., d’Angelo, M., Castelli, V., Catanesi, M., Iannotta, D., Giordano, A., Ippoliti, R., Benedetti, E., & Cimini, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071907 · Cited by 37 · see citing works

PPARGEpigenetic Deregulation and Its Role in Colorectal Tumorigenesis

Sabatino, L., Fucci, A., Pancione, M., & Colantuoni, V. (2012) · PPAR Research · doi:10.1155/2012/687492 · Cited by 37 · see citing works

Clinical Use of PPARγ Ligands in Cancer

Hatton, J. L., & Yee, L. D. (2008) · PPAR Research · doi:10.1155/2008/159415 · Cited by 36 · see citing works

Involvement of PPARα in the growth inhibitory effect of arachidonic acid on breast cancer cells

Bocca, C., Bozzo, F., Martinasso, G., Canuto, R. A., & Miglietta, A. (2008) · British Journal Of Nutrition · doi:10.1017/s0007114508942161 · Cited by 36 · see citing works

Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer

Garattini, E., Bolis, M., Gianni’, M., Paroni, G., Fratelli, M., & Terao, M. (2016) · Oncotarget · doi:10.18632/oncotarget.7410 · Cited by 36 · see citing works

New Insights into Anticarcinogenic Properties of Adiponectin

Delort, L., Jardé, T., Dubois, V., Vasson, M., & Caldefie‐Chezet, F. (2012) · Vitamins and hormones · doi:10.1016/b978-0-12-398313-8.00015-4 · Cited by 35 · see citing works

Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing

Yang, W., Li, Y., Song, X., Xu, J., & Xie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15721 · Cited by 35 · see citing works

Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study

Moreno-Vega, A. I., Vega-Riveroll, L. J., Ayala, T., Peralta, G., Torres-Martel, J. M., Rojas, J., Mondragón, P., Domínguez, A., Obaldía, R. D., Avecilla-Guerrero, C., et al. (2019) · Nutrients · doi:10.3390/nu11071623 · Cited by 35 · see citing works

Peroxisome proliferator-activated receptor δ confers resistance to peroxisome proliferator-activated receptor γ-induced apoptosis in colorectal cancer cells

Wang, D., Ning, W., Xie, D., Guo, L., & DuBois, R. N. (2011) · Oncogene · doi:10.1038/onc.2011.299 · Cited by 33 · see citing works

PPAR trilogy from metabolism to cancer

Nahle, Z. A. (2004) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000134360.30911.bb · Cited by 34 · see citing works

Deciphering the Roles of Thiazolidinediones and PPAR γ in Bladder Cancer

Chiu, M., McBeth, L., Sindhwani, P., & Hinds, T. D. (2017) · PPAR Research · doi:10.1155/2017/4810672 · Cited by 34 · see citing works

Peroxisome proliferator-activated receptors: Key regulators of tumor progression and growth

Asgharzadeh, F., Memarzia, A., Alikhani, V., Beigoli, S., & Boskabady, M. H. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102039 · Cited by 33 · see citing works

[Troglitazone sensitizes effect of epirubicin on breast cancer cells].

Sun, J., Meng, Z., Lv, J., & Sun, Y. (2006) · PubMed · Cited by 2 · see citing works

Peroxisome proliferator-activated receptor γ (PPARγ) ligand, troglitazone sensitizes breast cancer cells to tamoxifen-induced apoptosis

Kim, J., Lee, Y., Yu, H., Kim, B.-S., Youn, H. J., & Jung, S. H. (2007) · Molecular Cancer Therapeutics

Induction of cell cycle arrest and apoptosis in breast cancer cells by troglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligand.

Youn, H. J., Lee, B., Jung, S., Park, M., Yoon, J., Lee, J., & Choi, M. S. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-5034

Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers

Yee, L. D., Williams, N., Wen, P., Young, D. C., Lester, J., Johnson, M. V., Farrar, W. B., Walker, M. J., Povoski, S. P., Suster, S. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1947 · Cited by 98 · see citing works

The effects of rosiglitazone therapy in early stage breast cancer

Yee, L. D., Williams, N., Wen, P., Young, D. C., Lester, J., Johnson, M. V., Farrar, W. B., Walker, M. J., Povoski, S. P., Suster, S. M., et al. (2006) · Cancer Research